Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.
Website: bio-techne.com



Growth: Pretty weak revenue growth rate 2.6%, there is slowdown compared to average historical growth rates 15.4%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +11.1%

Profitability: LTM EBITDA margin is positive, +42.7%. On average the margin is decreasing unsteadily. Gross margin is high, +66.9%. In the last quarter the company beat the estimated EPS, 0.0%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.5%. Free cash flow yield -2.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 25.1% higher than minimum and 50.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.2x by EV / Sales multiple , the company can be 56.1% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.8 mln (-0.007% of cap.)

Key Financials (Download financials)

Ticker: TECH
Share price, USD:  (+3.2%)66.1
year average price 73.20  


year start price 79.23 2023-05-01

max close price 89.42 2023-07-21

min close price 52.83 2023-11-01

current price 66.10 2024-04-29
Common stocks: 158 130 000

Dividend Yield:  0.5%
FCF Yield LTM: -2.4%
EV / LTM EBITDA: 22.2x
EV / EBITDA annualized: 31.3x
Last revenue growth (y/y):  2.6%
Last growth of EBITDA (y/y):  1.2%
Historical revenue growth:  15.4%
Historical growth of EBITDA:  22.5%
EV / Sales: 9.5x
Margin (EBITDA LTM / Revenue): 42.7%
Fundamental value created in LTM:
Market Cap ($m): 10 452
Net Debt ($m): 401
EV (Enterprise Value): 10 853
Price to Book: 5.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-12PRNewsWire

BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM

2024-02-01Zacks Investment Research

Here's What Key Metrics Tell Us About Techne (TECH) Q2 Earnings

2024-02-01Zacks Investment Research

Techne (TECH) Q2 Earnings and Revenues Lag Estimates

2023-11-20Seeking Alpha

Bio-Techne: Quality Play Struggles But Looks More Compelling

2023-10-31Zacks Investment Research

Techne (TECH) Q1 Earnings and Revenues Miss Estimates

2023-08-08Zacks Investment Research

Techne (TECH) Reports Q4 Earnings: What Key Metrics Have to Say

2023-08-08Zacks Investment Research

Techne (TECH) Meets Q4 Earnings Estimates

2023-05-18Seeking Alpha

Bio-Techne Corporation: Long-Term Quality, But At A Price

2023-05-12PRNewsWire

BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

2023-05-03Seeking Alpha

Bio-Techne Corporation (TECH) Q3 2023 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TECH TECH TECH TECH TECH TECH
reportedCurrency USD USD USD USD USD USD
cik 842 023 842 023 842 023 842 023 842 023 842 023
fillingDate 2024-02-07 2023-11-07 2023-08-23 2023-05-08 2023-02-07 2022-11-07
acceptedDate 2024-02-07 16:31:56 2023-11-07 16:35:57 2023-08-23 16:30:51 2023-05-08 16:30:53 2023-02-07 16:30:38 2022-11-07 16:31:06
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
revenue 273M 277M 301M 294M 272M 270M
costOfRevenue 96M 92M 97M 92M 88M 90M
grossProfit 177M 185M 205M 202M 183M 180M
grossProfitRatio 0.648 0.669 0.679 0.687 0.675 0.666
researchAndDevelopmentExpenses 23M 24M 23M 23M 22M 24M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 116M 105M 87M 99M 93M 99M
otherExpenses 810 000 -6M -6M -15 000 -1M 0
operatingExpenses 139M 129M 110M 122M 115M 123M
costAndExpenses 235M 221M 207M 214M 204M 213M
interestIncome 816 000 890 000 1M 974 000 968 000 433 000
interestExpense 4M 5M 4M 15 000 2M 4M
depreciationAndAmortization 28M 29M 27M 27M 27M 27M
ebitda 66M 84M 121M 107M 95M 83M
ebitdaratio 0.240 0.305 0.403 0.364 0.348 0.308
operatingIncome 38M 56M 95M 80M 68M 56M
operatingIncomeRatio 0.139 0.202 0.314 0.273 0.250 0.209
totalOtherIncomeExpensesNet -1M -6M -6M -15 000 -1M 47M
incomeBeforeTax 33M 50M 88M 80M 66M 104M
incomeBeforeTaxRatio 0.122 0.179 0.293 0.273 0.245 0.385
incomeTaxExpense 6M -1M 13M 10M 16M 14M
netIncome 27M 51M 75M 70M 50M 90M
netIncomeRatio 0.101 0.184 0.251 0.239 0.184 0.332
eps 0.170 0.320 0.480 0.450 0.320 0.570
epsdiluted 0.170 0.310 0.470 0.430 0.310 0.550
weightedAverageShsOut 158M 158M 158M 157M 157M 157M
weightedAverageShsOutDil 160M 162M 162M 162M 162M 162M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TECH TECH TECH TECH TECH TECH
reportedCurrency USD USD USD USD USD USD
cik 842 023 842 023 842 023 842 023 842 023 842 023
fillingDate 2024-02-07 2023-11-07 2023-08-23 2023-05-08 2023-02-07 2022-11-07
acceptedDate 2024-02-07 16:31:56 2023-11-07 16:35:57 2023-08-23 16:30:51 2023-05-08 16:30:53 2023-02-07 16:30:38 2022-11-07 16:31:06
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 130M 149M 181M 127M 165M 165M
shortTermInvestments 6M 0 24M 30M 32M 38M
cashAndShortTermInvestments 136M 149M 204M 157M 197M 203M
netReceivables 207M 205M 218M 216M 185M 174M
inventory 181M 186M 172M 169M 160M 150M
otherCurrentAssets 40M 52M 27M 28M 23M 25M
totalCurrentAssets 591M 591M 621M 571M 565M 552M
propertyPlantEquipmentNet 335M 334M 325M 322M 308M 294M
goodwill 980M 969M 873M 871M 870M 865M
intangibleAssets 551M 579M 535M 553M 568M 586M
goodwillAndIntangibleAssets 1 531M 1 548M 1 407M 1 424M 1 437M 1 451M
longTermInvestments 250M -83M -89M 0 0 0
taxAssets 72M 83M 89M 95M 111M 0
otherNonCurrentAssets -47M 282M 285M 189M -58M 54M
totalNonCurrentAssets 2 140M 2 164M 2 017M 2 029M 1 798M 1 799M
otherAssets 0 0 0 0 0 0
totalAssets 2 731M 2 755M 2 639M 2 600M 2 363M 2 351M
accountPayables 32M 79M 77M 81M 69M 30M
shortTermDebt 13M 12M 11M 11M 11M 12M
taxPayables 7M 6M 12M 18M 25M 17M
deferredRevenue 28M 25M 23M 25M 22M 22M
otherCurrentLiabilities 63M 12M 17M 24M 27M 73M
totalCurrentLiabilities 135M 128M 129M 141M 128M 138M
longTermDebt 543M 537M 444M 463M 278M 329M
deferredRevenueNonCurrent 2M 1M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 72M 83M 89M 95M 111M 113M
otherNonCurrentLiabilities 16M 8M 11M 11M 18M 397M
totalNonCurrentLiabilities 632M 630M 544M 569M 408M 462M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 109M 110M 105M 104M 89M 77M
totalLiabilities 767M 758M 672M 710M 536M 600M
preferredStock 0 0 0 0 0 0
commonStock 2M 2M 2M 2M 2M 392 000
retainedEarnings 1 261M 1 328M 1 309M 1 247M 1 200M 1 163M
accumulatedOtherComprehensiveIncomeLoss -64M -78M -66M -74M -75M -92M
othertotalStockholdersEquity 764M 747M 722M 715M 701M 680M
totalStockholdersEquity 1 964M 1 998M 1 967M 1 890M 1 827M 1 751M
totalEquity 1 964M 1 998M 1 967M 1 890M 1 827M 1 751M
totalLiabilitiesAndStockholdersEquity 2 731M 2 755M 2 639M 2 600M 2 363M 2 351M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 731M 2 755M 2 639M 2 600M 2 363M 2 351M
totalInvestments 6M -83M 24M 30M 32M 38M
totalDebt 556M 550M 455M 474M 289M 342M
netDebt 426M 401M 274M 347M 124M 176M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TECH TECH TECH TECH TECH TECH
reportedCurrency USD USD USD USD USD USD
cik 842 023 842 023 842 023 842 023 842 023 842 023
fillingDate 2024-02-07 2023-11-07 2023-08-23 2023-05-08 2023-02-07 2022-11-07
acceptedDate 2024-02-07 16:31:56 2023-11-07 16:35:57 2023-08-23 16:30:51 2023-05-08 16:30:53 2023-02-07 16:30:38 2022-11-07 16:31:06
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
netIncome 27M 51M 75M 70M 50M 90M
depreciationAndAmortization 28M 29M 27M 27M 27M 27M
deferredIncomeTax -11M -12M -7M -16M -2M -5M
stockBasedCompensation 13M 10M -2M 10M 17M 14M
changeInWorkingCapital 19M 2M 82M -39M -17M -23M
accountsReceivables 5M 16M -38M 0 0 17M
inventory -4M 181 000 -1M -10M -8M -11M
accountsPayables 8M -3M -2M 6M -10M -1M
otherWorkingCapital 10M -11M 123M -35M 436 000 -28M
otherNonCashItems 7M -21M -92M -1M -10M -47M
netCashProvidedByOperatingActivities 83M 59M 83M 51M 64M 56M
investmentsInPropertyPlantAndEquipment -15M -14M -11M -12M -6M -10M
acquisitionsNet -3M -164M -101M -131M 0 -83M
purchasesOfInvestments -6M -2M 21M 21M 15M -15M
salesMaturitiesOfInvestments 6M 24M -29M -27M 12M 73M
otherInvestingActivites -6M 2M 116M -93M -21M 15M
netCashUsedForInvestingActivites -24M -154M -5M -241M -109 000 -20M
debtRepayment -58M -70M -20M 0 -65M -441M
commonStockIssued 70M 14M 0 0 0 0
commonStockRepurchased -80M -20M 0 0 0 -20M
dividendsPaid -13M -13M -13M -13M -13M -13M
otherFinancingActivites -1M 160M 8M 163M 5M 441M
netCashUsedProvidedByFinancingActivities -81M 72M -24M 151M -72M -32M
effectOfForexChangesOnCash 3M -9M -1M 2M 7M -12M
netChangeInCash -19M -32M 53M -37M -575 000 -7M
cashAtEndOfPeriod 130M 149M 181M 127M 165M 165M
cashAtBeginningOfPeriod 149M 181M 127M 165M 165M 173M
operatingCashFlow 83M 59M 83M 51M 64M 56M
capitalExpenditure -15M -14M -11M -12M -6M -10M
freeCashFlow 68M 46M 73M 39M 58M 47M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-01 ET (fiscal 2024 q2)
2023 q3
2023-10-31 ET (fiscal 2024 q1)
2023 q2
2023-08-08 ET (fiscal 2023 q4)
2023 q1
2023-05-03 ET (fiscal 2023 q3)
2022 q4
2023-02-02 ET (fiscal 2023 q2)
2022 q3
2022-11-01 ET (fiscal 2023 q1)
2022 q2
2022-08-06 ET (fiscal 2022 q4)
2022 q1
2022-05-04 ET (fiscal 2022 q3)
2021 q4
2022-02-01 ET (fiscal 2022 q2)
2021 q3
2021-11-02 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-01 11:30 ET
BIO-TECHNE DECLARES DIVIDEND
2024-02-01 11:30 ET
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2024 RESULTS
2024-01-29 12:00 ET
BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS
2024-01-25 12:00 ET
LUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION
2024-01-24 12:00 ET
SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex™ SYSTEM
2024-01-16 12:00 ET
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS
2024-01-05 12:00 ET
BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT
2024-01-04 12:00 ET
BIO-TECHNE TO SHOWCASE CELL AND GENE THERAPY MANUFACTURING TOOLS AT PHACILITATE ADVANCED THERAPIES WEEK 2024
2023-12-21 12:00 ET
BIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2023-12-20 12:00 ET
BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPY
2023-12-14 12:00 ET
LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS
2023-11-27 12:00 ET
BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE
2023-11-13 12:00 ET
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
2023-11-02 11:00 ET
ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE
2023-10-31 10:30 ET
BIO-TECHNE DECLARES DIVIDEND
2023-10-31 10:30 ET
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS
2023-10-25 13:00 ET
LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING
2023-10-19 11:00 ET
BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER
2023-10-16 11:00 ET
BIO-TECHNE ACHIEVES ISO 13485 CERTIFICATION FOR ITS WALLINGFORD, CT MANUFACTURING FACILITY
2023-10-10 11:00 ET
BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 31, 2023, TO ANNOUNCE FIRST QUARTER FISCAL 2024 FINANCIAL RESULTS
2023-09-28 10:00 ET
DR. JORDAN LASER AWARDED AMP MERITORIOUS SERVICE AWARD
2023-09-27 11:00 ET
SCIENTISTS AT CE PHARM CONFERENCE DESCRIBE HOW Maurice™ AND MauriceFlex™ SYSTEMS TRANSFORM THEIR PROTEIN ANALYSIS
2023-09-26 11:00 ET
BIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM
2023-09-25 11:00 ET
BIO-TECHNE ISSUES 2023 CORPORATE SUSTAINABILITY REPORT
2023-09-19 06:00 ET
Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform
2023-08-28 11:00 ET
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
2023-08-24 11:00 ET
BIO-TECHNE ANNOUNCES 2023 INVESTOR DAY AND WEBCAST
2023-08-15 11:00 ET
BIO-TECHNE TO PRESENT AT THE UBS MEDTECH, TOOLS AND GENOMICS SUMMIT 2023
2023-08-14 11:00 ET
BIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE PHENOCYCLER FUSION
2023-08-08 10:30 ET
BIO-TECHNE DECLARES DIVIDEND
2023-08-08 10:30 ET
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS
2023-07-13 11:00 ET
BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 8, 2023, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2023 FINANCIAL RESULTS
2023-07-10 11:00 ET
BIO-TECHNE COMPLETES LUNAPHORE ACQUISITION
2023-06-22 12:00 ET
Lunaphore to Get Acquired by Bio-Techne
2023-06-22 12:00 ET
BIO-TECHNE TO ACQUIRE LUNAPHORE
2023-06-01 11:00 ET
BIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC
2023-05-25 11:00 ET
BIO-TECHNE TO PRESENT AT THE 2023 JEFFERIES HEALTHCARE CONFERENCE
2023-05-18 11:00 ET
EXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TEST
2023-05-16 11:00 ET
BIO-TECHNE COMMERCIALIZES RNASCOPE SPATIAL BIOLOGY WORKFLOW FOR THE STANDARD BIOTOOLS HYPERION IMAGING SYSTEM
2023-05-12 13:07 ET
BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
2023-05-10 11:00 ET
BIO-TECHNE ANNOUNCES LAUNCH OF KAPPA AND LAMBDA RNAscope ISH PROBES AS ANALYTE SPECIFIC REAGENTS (ASRs) FOR THE DETECTION OF IMMUNOGLOBULIN KAPPA AND LAMBDA LIGHT CHAINS mRNA
2023-05-03 10:30 ET
BIO-TECHNE DECLARES DIVIDEND
2023-05-03 10:30 ET
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2023 RESULTS
2023-05-02 11:00 ET
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES 2023 HEALTH CARE CONFERENCE
2023-04-17 11:00 ET
BIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC PARTNERSHIP TO DEVELOP THE FIRST FULLY AUTOMATED SAME-SLIDE SPATIAL MULTIOMICS SOLUTION
2023-04-13 11:00 ET
BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE
2023-04-12 11:00 ET
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 3, 2023, TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
2023-04-05 11:00 ET
BIO-TECHNE CELEBRATES MILESTONE WITH MORE THAN 1,000 ELLA™ INSTRUMENTS NOW IN OPERATION
2023-04-03 11:00 ET
BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING
2023-03-15 11:00 ET
BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM
2023-03-10 12:00 ET
BIO-TECHNE TO PRESENT AT THE BARCLAYS GLOBAL HEALTHCARE CONFERENCE
2023-03-01 12:00 ET
BIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF
2023-02-28 14:58 ET
BIO-TECHNE TO PRESENT AT THE COWEN 43rd ANNUAL HEALTH CARE CONFERENCE
2023-02-24 13:40 ET
ExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE
2023-02-22 12:00 ET
BIO-TECHNE TO PRESENT AT THE CITI 2023 HEALTHCARE SERVICES, MEDTECH, TOOLS & HCIT CONFERENCE
2023-02-14 12:00 ET
BIO-TECHNE AND CELL SIGNALING TECHNOLOGY ANNOUNCE PARTNERSHIP TO VALIDATE SIMPLE WESTERN ANTIBODIES
2023-02-02 11:30 ET
BIO-TECHNE RELEASES SECOND QUARTER FISCAL 2023 RESULTS
2023-02-02 11:30 ET
BIO-TECHNE DECLARES DIVIDEND
2023-01-31 12:00 ET
BIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSEL
2023-01-26 12:00 ET
BIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS
2023-01-17 12:00 ET
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
2023-01-10 12:00 ET
BIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT
2022-12-21 12:00 ET
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2022-12-05 12:00 ET
BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
2022-12-01 12:00 ET
Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market
2022-11-28 12:00 ET
BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
2022-11-17 12:00 ET
NAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS
2022-11-15 12:00 ET
BIO-TECHNE ANNOUNCES OPENING OF NEW IMMUNOASSAY MANUFACTURING FACILITY
2022-11-10 12:00 ET
BIO-TECHNE TO PRESENT AT THE STEPHENS ANNUAL INVESTMENT CONFERENCE
2022-11-08 12:00 ET
BIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCE
2022-11-03 11:00 ET
BIO-TECHNE TO PRESENT AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE
2022-11-01 10:30 ET
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2023 RESULTS
2022-11-01 10:30 ET
BIO-TECHNE DECLARES CASH DIVIDEND AND STOCK DIVIDEND
2022-10-31 11:00 ET
Asuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference
2022-10-18 11:00 ET
New Publication from Exosome Diagnostics Demonstrates Proof-of-Concept for Monitoring Astronaut Health in Space
2022-10-12 11:00 ET
BIO-TECHNE SETS A NEW STANDARD IN HIGHLY SENSITIVE RNA IMAGING WITH THE INTRODUCTION OF VIVID FLUORESCENT DYES FOR SPATIAL BIOLOGY
2022-10-11 11:00 ET
BIO-TECHNE INTRODUCES NEW SIMPLE PLEX AAV VIRAL TITER ASSAYS
2022-10-10 11:00 ET
BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
2022-10-06 11:00 ET
BIO-TECHNE COMMERCIALIZES AUTOMATED MULTI-OMIC RNASCOPE ASSAYS FOR SPATIAL VISUALIZATION OF RNA AND PROTEIN BIOMARKERS IN FFPE TISSUES
2022-10-03 11:00 ET
ScaleReady Introduces the Cue® Cell Processing System From Fresenius Kabi
2022-09-26 11:00 ET
Bio-Techne Files Patent Infringement Lawsuit Against Molecular Instruments
2022-09-21 11:00 ET
MAURICE FLEX™ icIEF ANALYSIS ADDS FRACTIONATION, ENABLING MASS SPEC PEAK CHARACTERIZATION
2022-09-19 11:00 ET
BIO-TECHNE ISSUES 2022 CORPORATE SUSTAINABILITY REPORT
2022-09-08 11:00 ET
BIO-TECHNE PRESENTS INITIAL DATA ON SJÖGREN'S SYNDROME MONITORING ASSAY

SEC forms

Show financial reports only

SEC form 10
2024-02-07 00:00 ET
Bio-Techne reported for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Bio-Techne published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Bio-Techne published news for 2023 q4
SEC form 8
2024-02-01 00:00 ET
Bio-Techne reported for 2023 q4
SEC form 10
2023-11-07 00:00 ET
Bio-Techne published news for 2023 q3
SEC form 8
2023-10-31 06:30 ET
Bio-Techne reported for 2023 q3
SEC form 10
2023-08-23 00:00 ET
Bio-Techne published news for 2023 q2
SEC form 6
2023-08-08 06:30 ET
Bio-Techne reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Bio-Techne published news for 2023 q2
SEC form 10
2023-05-08 00:00 ET
Bio-Techne reported for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Bio-Techne reported for 2023 q1
SEC form 6
2023-04-03 07:01 ET
Bio-Techne published news for 2023 q1
SEC form 6
2023-03-01 07:30 ET
Bio-Techne published news for 2022 q4
SEC form 10
2023-02-07 16:30 ET
Bio-Techne reported for 2022 q4
SEC form 10
2023-02-07 00:00 ET
Bio-Techne published news for 2022 q4
SEC form 6
2023-02-02 06:31 ET
Bio-Techne published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
Bio-Techne reported for 2022 q4
SEC form 6
2023-01-31 08:00 ET
Bio-Techne published news for 2022 q4
SEC form 10
2022-11-07 16:31 ET
Bio-Techne reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Bio-Techne reported for 2022 q3
SEC form 6
2022-11-01 06:32 ET
Bio-Techne published news for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Bio-Techne reported for 2022 q3
SEC form 6
2022-09-14 07:00 ET
Bio-Techne published news for 2022 q2
SEC form 6
2022-09-07 06:31 ET
Bio-Techne published news for 2022 q2
SEC form 6
2022-09-01 07:00 ET
Bio-Techne published news for 2022 q2
SEC form 10
2022-08-24 16:31 ET
Bio-Techne reported for 2022 q2
SEC form 10
2022-08-24 00:00 ET
Bio-Techne reported for 2022 q2
SEC form 6
2022-08-05 06:31 ET
Bio-Techne published news for 2022 q2
SEC form 6
2022-08-04 06:30 ET
Bio-Techne published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Bio-Techne reported for 2022 q2
SEC form 10
2022-05-09 16:30 ET
Bio-Techne reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Bio-Techne reported for 2022 q1
SEC form 6
2022-05-04 06:35 ET
Bio-Techne published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Bio-Techne reported for 2022 q1
SEC form 6
2022-04-27 16:32 ET
Bio-Techne published news for 2022 q1
SEC form 10
2022-02-07 16:30 ET
Bio-Techne published news for 2021 q4
SEC form 10
2022-02-07 00:00 ET
Bio-Techne published news for 2021 q4
SEC form 6
2022-02-01 06:30 ET
Bio-Techne published news for 2021 q4
SEC form 8
2022-02-01 00:00 ET
Bio-Techne published news for 2021 q4
SEC form 6
2021-12-22 16:30 ET
Bio-Techne published news for 2021 q3
SEC form 10
2021-11-08 16:32 ET
Bio-Techne published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Bio-Techne published news for 2021 q3
SEC form 6
2021-11-02 06:30 ET
Bio-Techne published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Bio-Techne published news for 2021 q3
SEC form 6
2021-10-29 16:31 ET
Bio-Techne published news for 2021 q3
SEC form 6
2021-09-14 16:05 ET
Bio-Techne published news for 2021 q2
SEC form 10
2021-08-25 16:46 ET
Bio-Techne published news for 2021 q2
SEC form 10
2021-08-25 00:00 ET
Bio-Techne published news for 2021 q2
SEC form 6
2021-08-05 06:32 ET
Bio-Techne published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Bio-Techne published news for 2021 q2
SEC form 10
2021-05-07 16:32 ET
Bio-Techne published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Bio-Techne published news for 2021 q1
SEC form 6
2021-05-06 06:33 ET
Bio-Techne published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Bio-Techne published news for 2021 q1
SEC form 10
2021-02-08 06:31 ET
Bio-Techne published news for 2020 q4
SEC form 6
2021-02-02 06:34 ET
Bio-Techne published news for 2020 q4
SEC form 10
2020-11-09 06:31 ET
Bio-Techne published news for 2020 q3
SEC form 6
2020-11-05 06:32 ET
Bio-Techne published news for 2020 q3
SEC form 6
2020-11-03 16:30 ET
Bio-Techne published news for 2020 q3
SEC form 6
2020-09-15 17:00 ET
Bio-Techne published news for 2020 q2